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Abstract In this paper we consider drug binding in the arterial wall following delivery
by a drug-eluting stent. Whilst it is now generally accepted that a non-linear saturable
reversible binding model is required to properly describe the binding process, the
precise formof the bindingmodel varies between authors.Our particular interest in this
manuscript is in assessing to what extent modelling specific and non-specific binding
in the arterial wall as separate phases is important. We study this issue by extending
a recently developed coupled model of drug release and arterial tissue distribution,
and comparing simulated profiles of drug concentration and drug mass in each phase
within the arterial tissue.
Keywords Drug-eluting stents · Receptor binding · Nonlinear saturable binding ·
Convection-diffusion-reaction equations
1 Introduction
Arterial stents are medical devices designed to widen the lumen of vessels which have
become narrowed as a result of atherosclerosis. It is now standard for these stents to
release antiproliferative/anti-inflammatory drugs into the arterial wall to control the
proliferation and migration of smooth muscle cells, which is linked to the develop-
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ment of restenosis (re-narrowing). These drug-eluting stents (DES) consist of a wired
scaffold, typically coated with a polymer that encapsulates the therapeutic drug. The
coating may include a rate-limiting barrier that provides a more controlled release.
Both the stent geometry and coating design should be optimized so that therapeutic
levels of drug are delivered to the arterial wall for the correct period of time. The evo-
lution from drug-free bare metal stents to DES has resulted in significantly reduced
restenosis rates, with the result that only around 5%of patients [1] now suffer from this
setback. However, there is still considerable scope to reduce restenosis rates further.
Another potentially more serious problem is the occurrence of late-stent thrombosis,
which has been associated with delayed healing of the arterial wall. This may result
from drug being retained in the arterial wall for longer than necessary, at concentra-
tions which prevent re-endothelialisation. Before one can fully optimise the release
kinetics, it is therefore essential to fully understand the binding of drug to components
in the wall.
Mathematical and computational (in silico) modelling has emerged as an extremely
useful tool to study the drug-release process and binding kinetics and to optimize the
stent design and physico-chemical parameters (see e.g. [2,3]). However, in silico
models alone are not sufficient. Indeed, a combination of models, ranging from in
vitro to ex vivo and in vivo are required if this problem is to be fully addressed [4].
Many in-silico model parameter values have been derived from experimental in vitro
and ex vivo studies whilst model validation typically requires in vivo measurements
of drug mass remaining on the stent and in the tissue [5].
It is generally accepted that drug transport within the stent coating is governed
by diffusion and possibly dissolution/degradation/erosion (depending on the physico-
chemical properties of the polymer carrier and of the drug), whilst transport within
the arterial wall is governed by diffusion, convection and binding. Early models of
binding assumed either equilibrium reactions or linear first order kinetics [6]. How-
ever, these have been shown to result in elevated and delayed peak wall concentrations
[7] which are inconsistent with experimental results. There is a plethora of literature
on more advanced non-linear mathematical models of drug binding. Whilst it is not
our intention to provide a review of the various published models, we mention here
some examples of non-linear binding models which have been applied to a variety of
different situations. Groh et al. [8] considered the interaction of a chemotherapeutic
agent with the microenvironment of cells in tumour drug delivery. They devised a
three compartment model which included a non-linear reaction to describe binding to
binding sites within cells. Vo and Meere [9] modelled the release of heparin-binding
growth factors from an affinity-based delivery system using a non-linear reversible
binding model. Ferreira et al. [10] presented a series of non-linear binding models
to describe the degradation of a PLA stent coating into lactic acid and oligomers. A
non-linear saturable binding model was adopted by Tzafriri et al. [11] and later by
Bozsak et al. [3,7] to describe drug binding to arterial tissue sites. The model included
two phases of drug in the tissue: free and bound. However, it is well established
that in addition to binding to specific receptors (SR), there is also the occurrence of
non-specific binding caused by association of drug with membrane constituents or
by trapping of drug in the extracellular medium [12]. Most recently, Tzafriri et al.
[5] included two equations for drug binding in arterial tissue: one for specific bind-
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ing to receptors and another for non-specific binding to general extracellular matrix
(ECM) sites. The result is three phases in the tissue: two bound (SR and ECM) and
one free.
In a recent paper [13], we outlined and emphasized the significance of modelling
release from a drug delivery device and the consequent transport in the contiguous
biological tissue as an intrinsically coupled system. In this manuscript we extend that
work to the particular application of DES to assess the importance (or otherwise) of
modelling specific and non-specific saturable binding in the arterial wall as separate
phases.
2 The mathematical model
We adopt the recent modelling framework of McGinty and Pontrelli [13] and extend
their model to include two distinct bound phases within the tissue. The model consists
of equations which describe drug diffusion and dissolution in the polymer coating,
diffusion, convection and saturable binding in the arterial wall, as well as interface
conditions to fully couple the release-uptake system and a series of initial and boundary
conditions. We briefly summarize the model here and, for full details, the reader is
referred to [13].
The coating ismodelled as a planar slab, enclosed on one sidewith the impermeable
strut and having the other side faced to the wall. In this configuration, as most of
the mass transport occurs in the direction normal to the tissue surface, we consider
a simplified one-dimensional case. Since the arterial wall thickness is very small
compared to the arterial radius, it is reasonable to use a Cartesian coordinate system,
with the x-axis representing the radial direction normal to the layer surface. The
location of the interface is given by x = 0, and l0, l1 are the thicknesses of the coating
and wall, respectively, with l1  l0 (Fig. 1).
Fig. 1 Schematic diagram showing the geometrical configuration and the reference system. The stent
is coated with a polymer which contains the drug. Following dissolution and diffusion in the coating,
dissolved drug enters the arterial wall. Here drug exists in the free phase, but also binds to non-specific
general extracellular matrix (ECM) sites and to specific receptors (SR)
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2.1 Modelling drug dynamics in the coating
Let b0 and c0 represent the concentrations of drug bound within the polymer matrix
and dissolved in the free phase, respectively. Initially all of the drug exists in solid
form in the bound phase at concentration B. When exposed to plasma, we assume that
the polymer becomes fully wetted, initiating a dissolution process whereby bound
drug dissolves into the free phase and subsequently diffuses through plasma before
being released into the arterial tissue. Since the diffusion of drug in the solid phase is
negligible, the equations for the drug dynamics in terms of concentrations b0 and c0
are
∂b0
∂t
= −β0b
2
3
0 (S − c0) in (−l0, 0), (1)
∂c0
∂t
= D0 ∂
2c0
∂x2
+ β0b
2
3
0 (S − c0) in (−l0, 0), (2)
where D0 (cm2 s−1) is the effective diffusion coefficient of the solute,
β0 (1/(s (mol cm−3)2/3)) is the dissolution rate and S is the solubility limit [14].
2.2 Modelling drug dynamics in the arterial wall
In the arterial wall, the free drug (c1) undergoes diffusion and convection due to a pres-
sure difference across the wall. In addition, the drug binds reversibly to components of
the tissue. Denoting the concentration of drug which is bound to non-specific general
ECM sites and SR by b1 and b2, respectively, then assuming the wall comprises a
single homogeneous layer with isotropic diffusion properties, the equations of drug
transport in the tissue are given by:
∂c1
∂t
= D1 ∂
2c1
∂x2
− v1 ∂c1
∂x
− k f1 c1
(
bmax1 − b1
) + kr1b1
− k f2 c1
(
bmax2 − b2
) + kr2b2 in (0, l1), (3)
∂b1
∂t
= k f1 c1
(
bmax1 − b1
) − kr1b1 in (0, l1), (4)
∂b2
∂t
= k f2 c1
(
bmax2 − b2
) − kr2b2 in (0, l1), (5)
where D1 is the diffusivity of the unbound drug and v1 (cm s−1) is themagnitude of the
convection which is assumed to act in the positive x direction. In the above equations,
k f and kr represent the forward and backward rate constants, bmax is the local density
of binding sites, and the subscripts 1 and 2 denote parameters with respect to the ECM
and SR phases, respectively. We note that by choosing k f2 = kr2 = 0 we return the
single bound phasemodel [13] (with the parameters k f1 and k
r
1 redefined to incorporate
both phases of binding).
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2.3 Boundary, interface and initial conditions
To close the two-layer coupled mass transfer system given by (1)–(5) we need to
assign appropriate boundary, interface and initial conditions. At the boundary with
the impermeable stent (x = −l0) and the adventitia (x = l1) we choose zero flux and
infinite sink conditions, respectively:
−D0 ∂c0
∂x
= 0 at x = −l0, (6)
c1 = 0 at x = l1. (7)
The zero-flux condition at x = −l0 assumes that no drug is lost to the flowing blood
in the lumen. This, of course, is a simplification, although it is not clear how much
drug is lost, given the limited solubility of the compounds used on DES and the fact
that many devices are now only coated with drug abluminally. Other authors [5] have
considered ‘efficiency factors’ to try to address this issue. One may also use a more
general Robin boundary condition. At the interface between the stent coating and the
arterial tissue we need two conditions. We impose continuity of flux and allow for a
possible concentration jump:
− D0 ∂c0
∂x
= −D1 ∂c1
∂x
+ v1c1 at x = 0, (8)
− D1 ∂c1
∂x
= P (c0 − c1) at x = 0, (9)
with P(cm s−1) the overall mass transfer coefficient. As initial conditions, we consider
that all drug is atmaximumconcentration in encapsulated form (b0 = B) in the coating,
and all the other concentrations are zero (c0 = c1 = b1 = b2 = 0).
3 Results
Before solving themodel equations, we follow the nondimensionalization presented in
[13], with all concentrations scaled by the initial bound drug concentration in the coat-
ing (B), spatial variables scaled by the thickness of the arterial wall (l1) and temporal
variables scaled by the diffusion timescale in the tissue (l21/D1). The resulting sys-
tem of nondimensionalized partial differential equations are then spatially discretized
using a standard finite difference scheme. At x = 0 no unique value for concentration
exists and no derivative can be computed across the interface, due to a possible dis-
continuity. The procedure proposed by [15] is adopted to get the concentration values
across the interface. The resulting non-linear system of ordinary differential equations
is solved by a Runge-Kutta type method with backward differentiation formulas, and
an adaptive time step. For full details of the solution method, we refer the reader to
[13].
In Table 1 we summarize the parameter values used in the simulations. These are
representative of a first generation DES (Cypher) which elutes the drug sirolimus.
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Table 1 Dimensional
parameter values used in the
simulations [5,13]
Parameter Simulated value
α 2/3
D0 1.2 × 10−12 cm2 s−1
l0 10−3 cm
β0 1 s−1 (mol cm−3)−2/3
B 10−4 mol cm−3
S B/10
P 10−6cm s−1
v 5.8 × 10−6 cm s−1
D1 2.5 × 10−6 cm2 s−1
l1 4.5 × 10−2 cm
k f1 2 × 106 (mol cm−3 s)−1
kr1 5.2 × 10−3 s−1
bmax1 3.63 × 10−7 mol cm−3
k f2 8 × 108 (mol cm−3 s)−1
kr2 1.6 × 10−4 s−1
bmax2 3.3 × 10−9 mol cm−3
0 0.5 1
0
2
4
6
8
10
12
x 10−6
x
c1
0 0.5 1
0
2
4
6
8
10
12
x 10−4
x
b1
0 0.5 1
0
0.5
1
1.5
2
2.5
3
x 10−5
x
b2
t=1 hour
t=15 days
t=30 days
Fig. 2 Nondimensional concentration profiles in the arterial wall at three times. Free (c1), ECM bound
(b1) and SR bound drug (b2) are displayed
In order to examine the effect of treating specific and non-specific binding as two
separate phases, in Fig. 2 we plot simulated concentration profiles of free drug, ECM
bound drug and SR bound drug. Drug enters the arterial wall (at x = 0) in the free-
phase and is rapidly bound to both ECM and SR sites. The free and ECM bound drug
concentration profiles rise to a peak (not shown) before decaying with time as drug
traverses through the tissue, is bound to SR and is absorbed at the adventitial boundary
(x = 1). Although the c1 and b1 profile shapes are similar, drug concentrations within
theECMboundphase are an order ofmagnitude greater than theSRboundphasewhich
in turn are tenfold greater than the free drug concentrations. Within the first hour, SR
spanning half the thickness of the tissue are saturated: these remain saturated for the
duration of the 30days studied (Fig. 3). The remaining SR sites become saturated in
the subsequent hours and they too remain at saturation levels for the duration of the
30days.
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Fig. 3 Nondimensional concentration profiles in the arterial wall at three times. Drug bound to non-specific
ECM sites (b1) and SR (b2) are displayed as a % of their respective saturation levels
Fig. 4 Nondimensional drug mass in each phase as a function of time. Mc1, Mb1 and Mb2 represent the
nondimensional mass of drug contained within the free, ECM bound and SR bound phases, respectively.
The inset is a magnification of the SR bound and free drug mass over the first 24h
However, Fig. 3 reveals that ECM sites are not saturated. Indeed, ECM bound
concentrations are only around 30% of saturation levels close to the lumen at 1h,
and this percentage decreases rapidly with increasing x . By 30days, ECM bound
concentrations are at<10%of saturation levels throughout the arterialwall. Therefore,
our results demonstrate that drug delivered to the arterial wall from the stent is too
low to occupy a large proportion of ECM binding sites, yet is high enough to saturate
SR. This is in agreement with Tzafriri et al. [5].
It is also possible to simulate the mass of drug contained within each phase in the
arterial wall. This can be achieved easily from the model by simply integrating the
various concentrations over the spatial domain. In Fig. 4 we observe that significantly
more drug is contained within the ECM bound phase than the other two phases, with
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the free drug phase containing the lowest amounts of drug. The peak of the free drug
mass and the ECM bound drug mass occurs at the same time (approximately 10 h):
however, the mass of drug in the SR bound phase peaks at saturation levels within the
first 4h.
4 Discussion
The goal of this work was to determine the importance (or otherwise) of modelling
specific and non-specific saturable reversible binding in the arterial wall as separate
phases. Our results have demonstrated (at least for the case of sirolimus elution) that
the simulation of ECM bound and SR bound phases separately is indeed important if
the aim of the model is to demonstrate receptor saturation. When binding is simulated
as a single phase, it is not possible to capture the SR saturation: the single bound
phase (which includes ECM binding and SR binding) never reaches saturation due to
the large total number of binding sites. Since receptor saturation has been associated
with therapeutic effect [5], this has important implications if one is using the model a
priori to predict DES efficacy. The saturation of SR is a result of the combined high
binding rate and low binding site density. The significantly higher capacity of ECM
binding sites means that they are never saturated, at least for the rate of drug elution
from the Cypher stent. The relatively fast ECM unbinding rate (an order of magnitude
greater than the SR unbinding rate) results in ECM bound drug dissociating relatively
rapidly, and effectively acting as a further source for SR binding, thus ensuring that
SR saturation levels are maintained.
It is worth mentioning that the lack of ECM binding site saturation has implications
in terms of the type of binding model required. A saturable binding model is clearly
unnecessary and so ECM binding can reasonably be approximated by a first order
linear binding model (which has been shown to be a special case of the saturable
model [13]). This simplifies the mathematics and may potentially significantly reduce
computation time if the model presented here is extended to more complex geometries
in higher dimensions.
If, however, the aim of the mathematical model is to make comparisons with in
vivo experimental results, then our results show that it may not be important to model
specific and non-specific binding as separate phases. The reason for this is that, to the
best of our knowledge, it is not possible to discriminate between the mass of drug that
is bound to ECM sites and the mass of drug that is bound to SR. The current standard
is to measure the total mass of drug in the wall (often expressed as µg drug/g tissue)
[5]. We have demonstrated that the vast majority of drug is contained within the ECM
bound phase and so the simulation of a single bound phase (as in [13]) is sufficient to
compare with these experimental results.
5 Conclusions
A deeper understanding of drug release kinetics and tissue absorption is necessary for
the rational optimization of stent-based drug delivery systems. One of the methods
available to evaluate the characteristics of drug elution from the coating into the arterial
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wall and to optimize the physico-chemical parameters is mathematical modelling and
numerical simulation. In this paper we have built upon a previously published model
[13] and focused on the reversible and saturable binding processes in the vascular
tissue. The model is based on a two-layer multiple-phase system where a system of
partial differential equations describes both the dissolution and diffusion processes in
the polymeric layer as well as diffusion, convection and reaction in the tissue layer.
A number of simplifying assumptions have been made in the model. For example,
we have considered a one-dimensional model which cannot account for anisotropy.
Additionally, the arterial wall has a typical multi-layered structure, whereas we model
only one layer (the media). However, we believe that all the modeling assump-
tions we have made are appropriate for studying the question addressed in this
manuscript.
We point out that the results presented here are for the simulated case of sirolimus
release and absorption from the Cypher stent. Although sirolimus-derived compounds
are currently the most used drugs on DES, other drugs (e.g. paclitaxel) with different
modes of action are also used. Notwithstanding, when the ratios of SR to ECMbinding
site density (bmax2 /b
max
1 ) and of SR to ECM unbinding rate (k
r
2/k
r
1) are both small,
these conclusions likely hold.
Data
The data associated with this paper consists of the mathematical model which is
detailed in the text.
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